title: Sex hormone-binding globulin as a marker of the effect of hormonal treatment in Turner's syndrome.
abstract: OBJECTIVE
  In girls with Turner's syndrome a positive effect of growth hormone (GH) therapy on statutal growth has been well documented, in spite of the fact that the levels of GH and IGF-I in these patients are usually within the normal range. It is known that plasma levels of sex hormone-binding globulin (SHBG) are negatively associated with growth hormone (GH) and with [GF-I. Limited data on SHBG levels in these patients and only scarce reports on other than gonadal steroids in these patients are available so far. The major aim of this study was to find out whether SHBG does respond to GH treatment.
  
  
  METHODS
  Plasma levels of SHBG, estradiol, progesterone, testosterone and the adrenal steroids and their precursors, namely cortisol, 17alpha-hydroxyprogesterone, androstenedione, dehydroepiandrosterone and its sulfate were determined in 65 patients aged 2-23 years with Turner's syndrome. The patients were divided into 4 groups according to their actual treatment (untreated, sex steroids only, GH only, GH and sex steroids) and the differences between the groups were evaluated. With respect to dependence of SHBG and of steroids studied on age (with exception of cortisol), their values were expressed as per cents of medians of the physiological values.
  
  
  RESULTS
  As expected, low levels of sex steroids were found. As to the adrenal steroids, in general, their average levels were lower than in healthy subjects but still within the physiological limits. With one exception (androstenedione), no significant differences were found between the groups. The levels of cortisol were undistinguishable from healthy subjects. Absolute as well as relative SHBG levels in untreated group and in the group treated with estrogens were normal or even lower than those reported for normal subjects of the same chronological age. Significantly reduced absolute as well as relative SHBG levels in comparison to all other groups were found in GH treated children.
  
  
  CONCLUSIONS
  The results indicate that SHBG may serve as a sensitive biochemical marker of the response to the GH administration.
authors: Institute of Endocrinology, 119 94 Praha, Czech Republic. rhampl@endo.cz
authors: R
authors: R
authors: Hampl
authors: M
authors: M
authors: Snajderova
authors: J
authors: J
authors: Lebl
authors: L
authors: L
authors: Lisa
authors: M
authors: M
authors: Dvorakova
authors: M
authors: M
authors: Hill
authors: J
authors: J
authors: Sulcova
authors: L
authors: L
authors: Starka
mesh_terms: D019326:17-alpha-Hydroxyprogesterone / Q000097:blood; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000097:blood; D000328:Adult; D000735:Androstenedione / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D003687:Dehydroepiandrosterone / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D015592:Immunoradiometric Assay; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000627:therapeutic use; D011374:Progesterone / Q000097:blood; D012738:Sex Hormone-Binding Globulin / Q000032:analysis*; D013739:Testosterone / Q000097:blood; D014424:Turner Syndrome / Q000097:blood / Q000188:drug therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D015415:Biomarkers; D004967:Estrogens; D012738:Sex Hormone-Binding Globulin; D019382:Human Growth Hormone; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D011374:Progesterone; D004958:Estradiol; D019314:Dehydroepiandrosterone Sulfate; D007334:Insulin-Like Growth Factor I; D019326:17-alpha-Hydroxyprogesterone; D017258:Medroxyprogesterone Acetate